20 episodes

PeerView (PVI) is a leading provider of high-quality, innovative continuing education (CME/CE/CPE and MOC) for clinicians and their interprofessional teams. Combining evidence-based medicine and instructional expertise, PeerView activities improve the knowledge, skills, and strategies that support clinical performance and patient outcomes. PeerView makes its educational programming and expert-led presentations and symposia available through its network of popular podcast channels to support specific specialties and conditions. Each episode includes a link to request CME/CE credit for participation. PeerView is solely responsible for the selection of topics, the preparation of editorial content, and the distribution of all materials it publishes.

PeerView Infectious Diseases CME/CNE/CPE Audio Podcast PVI, PeerView Institute for Medical Education

    • Science

PeerView (PVI) is a leading provider of high-quality, innovative continuing education (CME/CE/CPE and MOC) for clinicians and their interprofessional teams. Combining evidence-based medicine and instructional expertise, PeerView activities improve the knowledge, skills, and strategies that support clinical performance and patient outcomes. PeerView makes its educational programming and expert-led presentations and symposia available through its network of popular podcast channels to support specific specialties and conditions. Each episode includes a link to request CME/CE credit for participation. PeerView is solely responsible for the selection of topics, the preparation of editorial content, and the distribution of all materials it publishes.

    Charles Vega, MD, FAAFP - Examining Novel Approaches to Improve the Management of Influenza: An Animated Exploration

    Charles Vega, MD, FAAFP - Examining Novel Approaches to Improve the Management of Influenza: An Animated Exploration

    Go online to PeerView.com/BNC860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, an influenza expert discusses the latest clinical evidence and current guideline recommendations on the use of antiviral therapy in the treatment of influenza. Upon completion of this accredited CE activity, participants should be better able to: Summarize guideline recommendations regarding the use of antiviral therapy in the treatment of influenza, especially for patients at high risk of complications, Compare currently available and novel/emerging antiviral therapies for the treatment of influenza with regard to mechanisms of action, efficacy, safety, tolerability, and dosing, Select antiviral treatment for both adult and pediatric patients with influenza based on the latest clinical evidence and current guideline recommendations.

    • 28 min
    Thomas F. Patterson, MD, FACP, FIDSA - Overcoming Challenges in the Diagnosis and Treatment of Invasive Fungal Infections: A Visual Guide for Clinicians on the Front Lines of Patient Care

    Thomas F. Patterson, MD, FACP, FIDSA - Overcoming Challenges in the Diagnosis and Treatment of Invasive Fungal Infections: A Visual Guide for Clinicians on the Front Lines of Patient Care

    Go online to PeerView.com/JZZ860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, an infectious diseases specialist provides guidance on improving the diagnosis and treatment of invasive fungal infections. Upon completion of this activity, participants will be able to: Describe the epidemiology and risk factors for invasive fungal infections in patients who are immunocompromised and/or immunosuppressed, Promptly evaluate high-risk patients with signs or symptoms that are suggestive of systemic fungal infection to mitigate the impact of delayed recognition and initiation of antifungal therapy, Discuss available diagnostic tests and emerging technologies to ensure early detection of invasive fungal infections, Outline the role of antifungal susceptibility testing in guiding therapeutic decision-making for invasive fungal infections, Optimize the efficacy, tolerability, and cost-effectiveness of antifungal therapy in individual patients with invasive fungal infections through targeted application of kinetic and dynamic principles.

    • 58 min
    Jesse Papenburg, MD, MSc, FRCPC - Reducing the Burden of Influenza on Children: An Exploration of Novel and Emerging Antiviral Therapy

    Jesse Papenburg, MD, MSc, FRCPC - Reducing the Burden of Influenza on Children: An Exploration of Novel and Emerging Antiviral Therapy

    Go online to PeerView.com/GFP860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, an expert in influenza discusses the use of antiviral therapy in pediatric patients with influenza. Upon completion of this activity, participants will be able to: Discuss the underutilization of antiviral treatment for both adult and pediatric patients in the management of influenza, despite recommendations from practice guidelines, Describe the benefits and shortcomings associated with the use of diagnostic assays in detecting influenza in terms of sensitivity, specificity, and convenience, Assess currently available and novel/emerging antiviral therapies for the treatment of pediatric patients with influenza, based on the latest clinical data concerning efficacy, safety, tolerability, dosing, and routes of administration, Select antiviral treatment for pediatric patients with influenza, based on the latest clinical evidence and current guideline recommendations.

    • 44 min
    Paul E. Sax, MD - Coronavirus Disease 2019 (COVID-19): Need-to-Know Information and Practical Guidance for Healthcare Professionals on the Front Lines of Patient Care

    Paul E. Sax, MD - Coronavirus Disease 2019 (COVID-19): Need-to-Know Information and Practical Guidance for Healthcare Professionals on the Front Lines of Patient Care

    Go online to PeerView.com/QDX860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, an expert in infectious diseases discusses guidance for healthcare professionals involved in the treatment of patients with COVID-19. Upon completion of this activity, participants will be able to: Describe the epidemiology and virology of coronavirus disease 2019 (COVID-19), Evaluate patients with suspected COVID-19 infection in accordance with current guidance from the Centers for Disease Control and Prevention (CDC), recognizing that recommendations may be adapted by state and local health departments to respond to rapidly changing local circumstances, Assess the efficacy, safety, and appropriate clinical utilization of current and emerging COVID-19 management and prevention strategies, Employ evidence-based protocols to provide appropriate care for patients with suspected or confirmed COVID-19.

    • 40 min
    Michael G. Ison, MD, MS, FIDSA, FAST - Overcoming Challenges in the Treatment of Influenza: Examining the Underuse of Antiviral Therapies and Exploring Novel Approaches

    Michael G. Ison, MD, MS, FIDSA, FAST - Overcoming Challenges in the Treatment of Influenza: Examining the Underuse of Antiviral Therapies and Exploring Novel Approaches

    Go online to PeerView.com/JFB860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, an expert in influenza discusses the use of available and emerging antiviral therapies for the treatment of influenza. Upon completion of this activity, participants will be able to: Recognize the underutilization of antiviral treatment in the management of influenza despite recommendations from practice guidelines, Summarize the mechanisms of action, efficacy, safety, tolerability, and dosing of currently available and novel/emerging antiviral agents for the treatment of influenza, Incorporate currently available and novel/emerging antiviral therapies into the treatment of patients with influenza according to the latest clinical evidence and guideline recommendations.

    • 47 min
    Roy F. Chemaly, MD, MPH, FIDSA, FACP - Changing the Paradigm of CMV Management: New Science and More Choices for Challenging Cases in the HCT Setting

    Roy F. Chemaly, MD, MPH, FIDSA, FACP - Changing the Paradigm of CMV Management: New Science and More Choices for Challenging Cases in the HCT Setting

    Go online to PeerView.com/ZXF860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Cytomegalovirus (CMV) is a leading opportunistic infection in immunocompromised patients, including allogeneic hematopoietic stem cell transplant (HCT) recipients, where primary infection or reactivation is associated with increased morbidity and mortality. Antiviral drugs are the mainstay for the prevention of CMV infection and disease, most commonly with valganciclovir. However, valganciclovir use is often associated with adverse drug reactions, most notably leukopenia and neutropenia, and its widespread use has led to the emergence of antiviral resistance. Foscarnet and cidofovir, however, are associated with nephrotoxicity. After many years of few tangible advances, we are now experiencing an exciting period characterized by novel antiviral agents for CMV. Indeed, letermovir was recently approved for CMV prophylaxis in allogeneic HCT recipients, and data suggest that maribavir has the potential to address the unmet need of treating relapsed or resistant CMV infections. In this activity, based on a live symposium, experts offer insight into managing CMV in HCT recipients in a new era of antiviral therapy. Foundational guidance is combined with a discussion of real cases. Hear about best practices in preventing CMV infection in patients undergoing HCT, as well as the potential role of novel antiviral therapies in resistant/refractory CMV. Upon completion of this activity, participants should be better able to: Discuss the burden of cytomegalovirus (CMV) infection among hematopoietic stem cell transplant (HCT) recipients, Assess the latest clinical trial data regarding novel strategies to prevent and treat CMV infection in the HCT setting, Employ strategies to prevent and treat CMV infection in individual HCT recipients, considering current evidence, expert recommendations, and clinical trial enrollment for appropriate patients.

    • 46 min

Top Podcasts In Science

Listeners Also Subscribed To